DS
IMCR icon

David Shaw’s Immunocore IMCR Stock Holding History

David Shaw’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9M Buy
405,116
+69,925
+21% +$2.07M 0.01% 1619
2026
Q1 		$10.1M Buy
335,191
+151,251
+82% +$4.89M 0.01% 1636
2025
Q4 		$6.38M Buy
+183,940
New +$6.49M ﹤0.01% 2106
2024
Q3 		– Sell
-19,515
Closed -$661K – 4692
2024
Q2 		$661K Sell
19,515
-120,579
-86% -$6.15M ﹤0.01% 3452
2024
Q1 		$9.11M Buy
140,094
+55,441
+65% +$3.8M 0.01% 1434
2023
Q4 		$5.78M Sell
84,653
-53,750
-39% -$2.79M 0.01% 1796
2023
Q3 		$7.18M Sell
138,403
-81,556
-37% -$4.83M 0.01% 1512
2023
Q2 		$13.2M Sell
219,959
-94,480
-30% -$5.39M 0.01% 1127
2023
Q1 		$15.5M Sell
314,439
-48,960
-13% -$2.75M 0.02% 1051
2022
Q4 		$20.7M Buy
363,399
+230,897
+174% +$13M 0.02% 891
2022
Q3 		$6.22M Buy
+132,502
New +$6.31M 0.01% 1838

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

David Shaw's IMCR Position: Q2 2026 in Review

David Shaw increased its Immunocore (IMCR) stake by 21% in Q2 2026, buying an estimated $2.07M and bringing the position to 405,116 shares worth $12.9M. The position accounts for 0.01% of the portfolio, ranked #1619.

David Shaw first reported a position in IMCR in Q3 2022 and has held it in 11 quarters since. The position peaked at $20.7M in Q4 2022. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • David Shaw held 405,116 shares of Immunocore worth $12.9M as of Q2 2026.
  • David Shaw bought 69,925 Immunocore shares in Q2 2026, an estimated $2.07M.
  • Immunocore made up 0.01% of David Shaw's portfolio in Q2 2026, its #1619 holding.
  • David Shaw first reported a position in Immunocore in Q3 2022 and has held it in 11 quarters since.
  • David Shaw's Immunocore position peaked at $20.7M in Q4 2022.
  • 136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.